Appendix 4E - Preliminary Financial Report
Filed with ASX · · 13 pages · English
Summary by 6ix AI
The report indicates a loss from ordinary activities after tax attributable to the owners of Noxopharm Ltd., which reflects a decrease compared to the previous year. No dividends were declared or paid during the current financial period, and the report is unaudited. The company focused on clinical trial preparations and drug development, particularly for its SOF-SKN™ platform aimed at treating inflammation and cancer.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Noxopharm
- New preclinical data supports immuno-oncology approach
- Quarterly Activities/Appendix 4C Cash Flow Report
- SOF-SKN manufacturing begins to ensure clinical trial readi
- New data confirms cancer-fighting potential
- Noxopharms Sofra assets to be presented at global conference
Later from Noxopharm
- Novel oligonucleotides data presented at Options Conference
- Trading Halt
- Voluntary Suspension
- Noxopharm Successfully Raises $1.5 Million via Placement
- Reinstatement to Quotation
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm